tbuckley/cabot-search huggingface dataset:
Re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094–108
Authors: Miao Liu, Peng Chen, Tao Li
Journal: European Urology (2023)
Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study
Authors: Kwabena Asare, Yukteshwar Sookrajh, Johan van der Molen, Thokozani Khubone, Lara Lewis, Richard J Lessells, Kogieleum Naidoo, Phelelani Sosibo, Rosemary van Heerden, Nigel Garrett, Jienchi Dorward
Journal: The Lancet Global Health (2023)

BackgroundDolutegravir (DTG) is recommended for second-line antiretroviral therapy (ART) after virological failure on first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens in people living with HIV in low-income and middle-income countries. We compared the effectiveness of DTG versus the previously recommended ritonavir-boosted lopinavir (LPV/r) regimen for second-line treatment in South Africa.MethodsIn this retrospective observational cohort study, we used routinely collected, de-identified data from 59 primary health-care facilities in eThekwini Municipality, KwaZulu-Natal, South Africa. We included people living with HIV aged 15 years or older with virological failure (defined as two consecutive viral loads of ≥1000 copies per mL at least 56 days apart) on first-line NNRTI-based ART containing tenofovir disoproxil fumarate (TDF) and who switched to second-line ART. Our primary outcomes were retention in care and viral suppression (<50 copies per mL) at 12 months after starting second-line treatment. We used modified Poisson regression models to compare these outcomes between second-line regimens (zidovudine [AZT]/emtricitabine or lamivudine [XTC]/DTG; TDF/XTC/DTG; and AZT/XTC/LPV/r).FindingsWe included 1214 participants in our study, of whom 729 (60%) were female and 485 (40%) were male, and whose median age was 36 years (IQR 30–42). 689 (57%) were switched to AZT/XTC/LPV/r, 217 (18%) to AZT/XTC/DTG, and 308 (25%) to TDF/XTC/DTG. Compared with AZT/XTC/LPV/r (75%), retention in care was higher with AZT/XTC/DTG (86%, adjusted risk ratio [aRR]=1·14, 95% CI 1·03–1·27; adjusted risk difference [aRD]=10·89%, 95% CI 2·01 to 19·78) but similar with TDF/XTC/DTG (77%, aRR=1·01, 0·94–1·10; aRD=1·04%, –5·03 to 7·12). Observed retention in care was lower with TDF/XTC/DTG than with AZT/XTC/DTG, although in multivariable analysis evidence for a difference was weak (aRR=0·89, 0·78–1·01, p=0·060; aRD=–9·85%, –20·33 to 0·63, p=0·066). Of 799 participants who were retained in care with a 12-month viral load test done, viral suppression was higher with AZT/XTC/DTG (59%; aRR=1·25, 1·06–1·47; aRD=11·57%, 2·37 to 20·76) and higher with TDF/XTC/DTG (61%; aRR=1·30, 1·14–1·48; aRD=14·16%, 7·14 to 21·18) than with AZT/XTC/LPV/r (47%).InterpretationThese findings from routine care support further implementation of WHO's recommendation to use DTG instead of LPV/r in people living with HIV who experience virological failure while receiving first-line NNRTI-based ART.FundingBill & Melinda Gates Foundation.TranslationFor the isiZulu translation of the abstract see Supplementary Materials section.
Analysis of type 2 diabetes heterogeneity with a tree-like representation: insights from the prospective German Diabetes Study and the LURIC cohort
Authors: Martin Schön, Katsiaryna Prystupa, Tim Mori, Oana P Zaharia, Kálmán Bódis, Maria Bombrich, Clara Möser, Iryna Yurchenko, Yuliya Kupriyanova, Klaus Strassburger, Pavel Bobrov, Anand T N Nair, Gidon J Bönhof, Alexander Strom, Graciela E Delgado, Sema Kaya, Rainer Guthoff, Norbert Stefan, Andreas L Birkenfeld, Hans Hauner, Jochen Seissler, Andreas Pfeiffer, Matthias Blüher, Stefan Bornstein, Julia Szendroedi, Svenja Meyhöfer, Sandra Trenkamp, Volker Burkart, Vera B Schrauwen-Hinderling, Marcus E Kleber, Alexander Niessner, Christian Herder, Oliver Kuss, Winfried März, Ewan R Pearson, Michael Roden, Robert Wagner, Hadi Al-Hasani, Bengt-Frederik Belgardt, Gidon J. Bönhof, Gerd Geerling, Christian Herder, Andrea Icks, Karin Jandeleit-Dahm, Jörg Kotzka, Oliver Kuss, Eckhard Lammert, Wolfgang Rathmann, Michael Roden, Sabrina Schlesinger, Vera Schrauwen-Hinderling, Julia Szendroedi, Sandra Trenkamp, Robert Wagner
Journal: The Lancet Diabetes & Endocrinology (2023)
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 randomised controlled trial
Authors: T Douglas Bradley, Alexander G Logan, Geraldo Lorenzi Filho, R John Kimoff, Joaquin Durán Cantolla, Michael Arzt, Stefania Redolfi, Gianfranco Parati, Takatoshi Kasai, Mark E Dunlap, Diego Delgado, Shoichiro Yatsu, Adriana Bertolami, Rodrigo Pedrosa, George Tomlinson, Jose M Marin Trigo, Claudio Tantucci, John S Floras
Journal: The Lancet Respiratory Medicine (2023)
Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Domenico Russo, Michael Schmitt, Sylvain Pilorge, Matthias Stelljes, Toshiro Kawakita, Valerie L Teal, Barbara Haber, Charlene Bopp, Sanjeet S Dadwal, Cyrus Badshah
Journal: The Lancet Haematology (2023)
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study
Authors: Christian Pfister, Gwenaelle Gravis, Aude Flechon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Michel Soulie, Yves Allory, Valentin Harter, Stéphane Culine, Géraldine PIGNOT, Jean Philippe FENDLER, Laurent GUY, Grégory VERHOEST, Nicolas MOTTET, Arnaud DOERFLER, Sophie ABADIE LACOURTOISIE, Abde Rahmene AZZOUZI, Pierre MONGIAT, Lionnel GEOFFROIS, Pascal ESCHWEGE, Frédéric DI FIORE, Guilhem ROUBAUD, Jean Luc HOEPFFNER, Philippe BARTHELEMY, Hervé LANG, Eric VOOG, Eric MANDRON, Jean Marc TOURANI, Camille SERRATE, Alexandre COLAU, Carolina SALDANA, Alexandre DE LA TAILLE, Thierry NGUYEN, François KLEINCLAUSS, Yohan LORIOT, Jacques IRANI, Jean Christophe EYMARD, Stéphane LARRE, Olivier HUILLARD, Marc ZERBIB, Frédéric ROLLAND, Jérôme RIGAUD, Nadine HOUEDE, Stéphane DROUPY, Georgina MALOUF, Morgan ROUPRET, Sabine VIEILLOT, Nicolas LETANG, Tiffen LHARIDON, Nicolas GASCHIGNARD, Werner HILGERS, Jean Louis DAVIN
Journal: The Lancet Oncology (2023)
Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC
Authors: Sabine Mueller, Cassie Kline, Andrea Franson, Jasper van der Lugt, Michael Prados, Sebastian M Waszak, Sabine L A Plasschaert, Annette M Molinaro, Carl Koschmann, Javad Nazarian
Journal: Neuro-Oncology (2023)

Background Diffuse midline glioma (DMG) is a devastating pediatric brain tumor unresponsive to hundreds of clinical trials. Approximately 80% of DMGs harbor H3K27M oncohistones, which reprogram the epigenome to increase the metabolic profile of the tumor cells. Methods We have previously shown preclinical efficacy of targeting both oxidative phosphorylation and glycolysis through treatment with ONC201, which activates the mitochondrial protease ClpP, and paxalisib, which inhibits PI3K/mTOR, respectively. Results ONC201 and paxalisib combination treatment aimed at inducing metabolic distress led to the design of the first DMG-specific platform trial PNOC022 (NCT05009992). Conclusions Here, we expand on the PNOC022 rationale and discuss various considerations, including liquid biome, microbiome, and genomic biomarkers, quality-of-life endpoints, and novel imaging modalities, such that we offer direction on future clinical trials in DMG.
PEGylated nanoparticles interact with macrophages independently of immune response factors and trigger a non-phagocytic, low-inflammatory response
Authors: Monireh Asoudeh, Nicole Nguyen, Mitch Raith, Desiree S. Denman, Uche C. Anozie, Mahshid Mokhtarnejad, Bamin Khomami, Kaitlyn M. Skotty, Sami Isaac, Taylor Gebhart, Lauren Vaigneur, Aga Gelgie, Oudessa Kerro Dego, Trevor Freeman, Jon Beever, Paul Dalhaimer
Journal: Journal of Controlled Release (2024)
Contact allergies to dental materials in patients
Authors: Susann Forkel, Steffen Schubert, Lisa Corvin, Guido Heine, Claudia C V Lang, Eva Oppel, Claudia Pföhler, Regina Treudler, Andrea Bauer, Mathias Sulk, Birger Kränke, Knut Schäkel, Annice Heratizadeh, Margitta Worm, Jana Witte, Johannes Geier, Timo Buhl
Journal: British Journal of Dermatology (2023)

Concerns regarding contact allergies and intolerance reactions to dental materials are widespread among patients. Development of novel dental materials and less frequent amalgam use may alter sensitization profiles in patients with possible contact allergy.
Furuncular myiasis caused by <i>Dermatobia hominis</i>: entodermoscopic findings
Authors: Patrizia E Aguilar-Calderón, Leslie M Garza-García, Elizabeth Brussolo-Marroquín, Adrian Cuellar-Barboza, Jorge Ocampo-Candiani, Lucía T Fernández
Journal: British Journal of Dermatology (2023)

A 27-year-old male traveller returning from the Amazon forest came to our dermatology consultation with a furuncle-like nodule in the temporal region. During examination we observed an erythematous nodule with a central opening. We describe the entodermoscopic characteristics of Dermatobia hominis.
Accurate detection of identity-by-descent segments in human ancient DNA
Authors: Harald Ringbauer, Yilei Huang, Ali Akbari, Swapan Mallick, Iñigo Olalde, Nick Patterson, David Reich
Journal: Nature Genetics (2023)

Abstract Long DNA segments shared between two individuals, known as identity-by-descent (IBD), reveal recent genealogical connections. Here we introduce ancIBD, a method for identifying IBD segments in ancient human DNA (aDNA) using a hidden Markov model and imputed genotype probabilities. We demonstrate that ancIBD accurately identifies IBD segments &gt;8 cM for aDNA data with an average depth of &gt;0.25× for whole-genome sequencing or &gt;1× for 1240k single nucleotide polymorphism capture data. Applying ancIBD to 4,248 ancient Eurasian individuals, we identify relatives up to the sixth degree and genealogical connections between archaeological groups. Notably, we reveal long IBD sharing between Corded Ware and Yamnaya groups, indicating that the Yamnaya herders of the Pontic-Caspian Steppe and the Steppe-related ancestry in various European Corded Ware groups share substantial co-ancestry within only a few hundred years. These results show that detecting IBD segments can generate powerful insights into the growing aDNA record, both on a small scale relevant to life stories and on a large scale relevant to major cultural-historical events.
Clinical-pathologic characteristics of true interval and screen-detected breast cancer among participants in a Canadian breast screening program: A nested case-control study
Authors: D. Rayson, J. I. Payne, P. J. Barnes, R. MacIntosh, M. Abdolell, T. Foley, T. Younis, J. Caines
Journal: Journal of Clinical Oncology (2008)

638 Background: The interpretation of clinical and biologic differences between screen-detected and interval breast cancers has been limited by the failure to control for factors known to influence breast cancer biology, such as age at diagnosis, as well as for differences in recommended screening intervals between age groups. Methods: A case-control study nested within the participants of the population-based Nova Scotia Breast Screening Program diagnosed between ages 40–69 in the period 1991–2006 was performed. Interval cases were selected as having developed after a negative screen and prior to the recommended next screen and were validated by blinded review of the pre-diagnosis screening mammogram by 3 mammographers, 2 of whom had to agree that the screening exam was negative. Screen-detected cases were matched to intervals on a 2:1 basis by 5-year age group and recommended screening interval (40–49 yo, annual; 50–69 yo + family history, annual; 50–69 yo - family history biennial). Results: 240 interval cancers were identified of which 38% were grade 3 lesions and 31.7% had LVI. Selected comparisons to controls are presented in Table 1. For those with currently available data, ER/PR/HER2 results (intervals vs screen-detected) were; ER+ 73% vs 78.5%, PR+ 65.4% vs 72.5%, HER2+ 17% vs 26.7%. Conclusions: Controlling for age and screening interval, interval breast cancers are significantly larger and significantly more frequently node-positive at diagnosis compared to screen-detected cancers. They are also more likely to be of lobular histology and have a triple-negative phenotype. A Comparison of Selected Variables between Interval Cases and Controls Matched for Age at Diagnosis and Screening Interval Age at diagnosis 40–49 50–69 50–69 Recommended screening interval 1yr 1yr 2yr Cancer detection Interval Screen Interval Screen Interval Screen Sample size 37 74 41 82 162 324 Invasive disease (%) 100 75.7 95.1 79.3 91.3 78.7 * for all age groups Size-mms (mean) 23.3 13.2 17.8 12.1 18.9 11.5 * for all age groups Positive lymph nodes (%) 46 20.3 31.7 20.7 37.6 15.1 *40–49 and 50–69, 2yr interval Triple negative (%) 12.5 0 16.7 11.1 23.4 5.3 Invasive lobular (%) 8.1 4 12.2 6.1 7.4 7.1 * p < 0.05 No significant financial relationships to disclose.
Assessment of implementation strategies adopted for antimicrobial stewardship interventions in long-term care facilities: a systematic review
Authors: Michèle Conlin, Marie Hamard, Nelly Agrinier, Gabriel Birgand, Patrick Castel, Frédérique Claudot, Catherine Dumartin, Jonathan Epstein, Laetitia Ricci
Journal: Clinical Microbiology and Infection (2023)
Long-term neuropsychiatric sequelae of Delta versus Omicron SARS-CoV-2 infection
Authors: Liang En Wee, Jue Tao Lim, An Ting Tay, Deanette Pang, Borame Dickens, Calvin J. Chiew, Benjamin Ong, David Chien Boon Lye, Kelvin Bryan Tan
Journal: Clinical Microbiology and Infection (2023)
Salivary α-amylase as a marker of sleep disorders: A theoretical review
Authors: Marine Thieux, Aurore Guyon, Laurent Seugnet, Patricia Franco
Journal: Sleep Medicine Reviews (2023)

Sleep disorders are commonplace in our modern societies. Specialized hospital departments are generally overloaded, and sleep assessment is an expensive process in terms of equipment, human resources, and time. Biomarkers would usefully complement current measures in the screening and follow-up of sleep disorders and their daytime repercussions. Among salivary markers, a growing body of literature suggests that salivary α-amylase (sAA) may be a cross-species marker of sleep debt. However, there is no consensus as to the direction of variation in sAA with sleep disorders. Herein, after describing the mechanisms of sAA secretion and its relationship with stress, studies assessing the relationship between sAA and sleep parameters are reviewed. Finally, the influence of confounding factors is discussed, along with methodological considerations, to better understand the fluctuations in sAA and facilitate future studies in the field.
Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements
Authors: Rupesh Raina, Swathi Jothi, Dieter Haffner, Michael Somers, Guido Filler, Prabhav Vasistha, Ronith Chakraborty, Ron Shapiro, Parmjeet S. Randhawa, Rulan Parekh, Christopher Licht, Timothy Bunchman, Sidharth Sethi, Guneive Mangat, Joshua Zaritsky, Franz Schaefer, Bradley Warady, Sharon Bartosh, Mignon McCulloch, Khalid Alhasan, Agnieszka Swiatecka-Urban, William E. Smoyer, Anil Chandraker, Hui Kim Yap, Vivekanand Jha, Arvind Bagga, Jai Radhakrishnan
Journal: Kidney International (2023)

Focal segmental glomerular sclerosis (FSGS) is 1 of the primary causes of nephrotic syndrome in both pediatric and adult patients, which can lead to end-stage kidney disease. Recurrence of FSGS after kidney transplantation significantly increases allograft loss, leading to morbidity and mortality. Currently, there are no consensus guidelines for identifying those patients who are at risk for recurrence or for the management of recurrent FSGS. Our work group performed a literature search on PubMed/Medline, Embase, and Cochrane, and recommendations were proposed and graded for strength of evidence. Of the 614 initially identified studies, 221 were found suitable to formulate consensus guidelines for recurrent FSGS. These guidelines focus on the definition, epidemiology, risk factors, pathogenesis, and management of recurrent FSGS. We conclude that additional studies are required to strengthen the recommendations proposed in this review.
Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19
Authors: Maddalena Peghin, Maria De Martino, Alvisa Palese, Stefania Chiappinotto, Federico Fonda, Valentina Gerussi, Assunta Sartor, Francesco Curcio, Paolo Antonio Grossi, Miriam Isola, Carlo Tascini
Journal: Clinical Microbiology and Infection (2023)

ObjectivesTo describe the dynamics and factors related with natural and hybrid humoral response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and risk of reinfection among first wave patients.MethodsA prospective longitudinal study with periodic serological follow-up after acute onset of all recovered patients with SARS-CoV-2 infection cared in Udine Hospital (March-May 2020). Nucleocapsid (N) protein and spike receptor-binding domain (S-RBD) antibody tests were used to distinguish natural and vaccine induced response.ResultsOverall, 153 patients (66 men, mean age 56 years) were followed for a median of 27.3 (IQR 26.9-27.8) months. Seroreversion was 98.5% (95% CI 96.8-99.4) for SARS-CoV-2-N IgM at 1 year and 57.4% (95% CI 51.5-63.5) for SARS-CoV-2-N IgG at 2 years. Initial serological response (HR 0.99, 95% CI 0.99-0.99, p=0.002 for IgM and HR 0.97, 95% CI 0.97-0.98, p<0.001 for IgG) and severity of acute infection (HR 0.62, 95% CI 0.39-0.96, p=0.033 for IgM and HR 0.60, 95% CI 0.37-0.99, p<0.001 for IgG) were independently associated with persistent SARS-CoV-2-N IgM/IgG response. Older age and smoker status were associated with long-term SARS-CoV-2-N IgM and SARS-CoV-2-N IgG respectively (HR 0.75, 95% CI 0.57-0.98, p=0.038; HR 1.77, 95% CI 1.19-2.61, p=0.004 respectively). All patients maintained SARS-CoV-2-S-RBD IgG response at 24 months follow-up. Reinfections occurred in 25/153 (16.3%) patients, mostly during the omicron circulation. Reinfection rates did not differ significantly between SARS-CoV-2-N IgG seronegative and seropositive patients (14/89, 15.7% vs 10/62, 16.1%, p=0.947). Unvaccinated patients had higher risk of reinfection (4/7, 57.1% vs vaccinated 21/146, 14.4%, p=0.014).ConclusionsFirst wave patients had durable natural humoral immunity in 40% and anti-S-RBD response in 100% up to two years after infection. Natural humoral response alone was not protective against reinfections with omicron SARS-CoV-2 variants, whereas vaccination was effective to reduce the risk of a new infection.
Establishing ground truth of polyp size, morphology, and volume using three-dimensional scanning
Authors: Roupen Djinbachian, Mahsa Taghiakbari, Firas Mubaid, Chakib Yahia Rekkabi, Bibi Nuzha Noorah, Daniel von Renteln
Journal: Endoscopy (2023)

Establishing ground truth of polyp size, morphology, and volume using three-dimensional scanning Comprehensive artificial intelligence (AI) solutions that should cover detecting polyp morphology, size, and volume are being developed. To train such AI solutions, it is essential to obtain high quality reference (ground truth data) on polyp morphology, size, and volume.
Cholangioscopy-assisted partial stent-in-stent method useful for bilateral biliary drainage of hilar cholangiocarcinoma
Authors: Hideaki Kazumori, Yasuhiko Ohno, Kousaku Kawashima
Journal: Endoscopy (2023)

Bilateral drainage with the use of a partial stent-in-stent method is well known to resolve bile duct obstruction associated with a hilar cholangiocarcinoma. Unfortunately, the results are sometimes unsatisfactory because of the difficulty passing the guidewire through the targeted bile ducts, with reported success rates ranging from 80–95% [1] [2] [3]. Presented here is a novel cholangioscopy method.
Novel use of a colonic intraprocedural cleansing device for upper gastrointestinal bleeding
Authors: Tessa Herman, Morgan Freeman, Nicha Wongjarupong, Vijay Are, Long B. Le, Mohammad Bilal, Brian J. Hanson
Journal: Endoscopy (2023)

A 74-year-old patient with iron deficiency anemia presented for an outpatient upper endoscopy. Two 20–30 mm pedunculated polyps were detected in the gastric body ([Fig. 1]) and removed with a hot snare. Polypectomy bleeding prompted hemostatic clip placement. However, bleeding persisted, and endoscopic visualization was compromised. The endoscope was exchanged for one with a larger suction channel, but visualization remained inadequate. Therefore, the Pure-Vu EVS System (Motus GI, Tirat Carmel, Israel), a US Food and Drug Administration-approved oversleeve-based intraprocedural cleansing device intended for use in the colon ([Fig. 2]), was used to improve visualization, allowing further hemostatic interventions.
A novel dedicated nonslip short-length balloon catheter for treating hepaticojejunostomy anastomotic stricture in balloon enteroscopy-assisted ERCP
Authors: Tadahisa Inoue, Mayu Ibusuki, Rena Kitano, Kiyoaki Ito
Journal: Endoscopy (2023)

Hepaticojejunostomy anastomotic strictures (HJASs) often occur as an adverse event after biliary reconstructive surgery [1]. Balloon stricture dilation via balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography (BE-ERCP) is a standard treatment for HJAS [2]; however, there is no dedicated balloon catheter for HJAS treatment. Conventional papillary/bile duct dilation balloons are generally used, but they are often too long for HJASs. Long balloons can unnecessarily expand the normal intrahepatic bile duct and require there to be sufficient distance between the anastomotic site and the tip of the scope, which can be challenging to achieve. In contrast, short balloons tend to slip during inflation, especially during BE-ERCP because of the absence of a forceps elevator.
A syringe method for esophageal Lugol’s iodine chromoendoscopy
Authors: Kai Liu, Jiawei Bai, Li Gao, Xin Dong, Ying Han, Zhiguo Liu
Journal: Endoscopy (2023)

Lugol's iodine chromoendoscopy is the method commonly used to detect and diagnose esophageal squamous cell carcinoma [1] [2]. The conventional method of spraying iodine requires iodine solution diluted from the stock solution, a spraying catheter, and cooperation between the endoscopist and the assistant. Here, we report a novel syringe method for iodine spraying without the above requirements.
Novel strategy of hold-and-drag clip closure with mantis-like claw for post-gastric endoscopic submucosal dissection defect of &lt;30 mm
Authors: Noriko Nishiyama, Takanori Matsui, Kaho Nakatani, Kazuhiro Kozuka, Naoya Tada, Tatsuo Yachida, Hideki Kobara
Journal: Endoscopy (2023)

Endoscopic closure of post-endoscopic submucosal dissection (ESD) defects can reduce postoperative adverse events [1]. Innovative techniques such as use of an endoloop [2], endoscopic ligation with O-ring closure [3], and reopenable clip over the line method [4] have recently been developed; however, the complexity and time-consuming nature of such procedures remain problematic. We introduce a closure strategy using a new endoclip with a mantis-like claw (MANTIS Clip; Boston Scientific, Marlborough, Massachusetts, USA) ([Fig. 1]) that enables a secure hold-and-drag maneuver and defect approximation in gastric post-ESD defects ([Fig. 2]).